| NCT05329545 | III | High grade serous NaPi2b+ ovarian cancer with platinum-sensitive recurrence and CR, PR or SD in most recent platinum-based therapy; no avastin with most recent platinum-based therapy (maintenance) | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT) | AZ, CA, CO, FL, GA, IL, LA, ME, MD, MI, MN, MO, MT, NE, NV, NJ, NM, NY, NC, OH, OK, OR, PA, RI, SD, TN, TX, VA, WI | View Drugs | View Results |